Medicine and Dentistry
Congestive Heart Failure
100%
Diabetes
52%
Maturity Onset Diabetes of the Young
38%
Cardiovascular System
27%
Cardiorespiratory
21%
Biological Marker
20%
Heart Failure with Preserved Ejection Fraction
18%
Patient with Type 2 Diabetes
15%
Prevalence
15%
Cardiovascular Disease
14%
Physical Activity
14%
Cardiac Troponin
14%
Hazard Ratio
13%
Health System
13%
Amino Terminal Sequence
13%
Coronary Artery Calcium
12%
Obesity
12%
Natriuretic Factor
12%
Body Mass Index
12%
Cardiovascular Risk
12%
Ejection Fraction
11%
Chronic Kidney Disease
10%
Outpatient
10%
Cohort Analysis
10%
Impaired Glucose Tolerance
9%
Brain Natriuretic Peptide
9%
Troponin T
8%
Liraglutide
8%
Heart Muscle Injury
8%
Diseases
8%
Lifestyle Intervention
7%
Randomized Clinical Trial
7%
Mortality Rate
7%
Proportional Hazards Model
7%
Myocardial Disease
7%
Patient with Diabetes
7%
Diabetic Cardiomyopathy
7%
Sodium Glucose Cotransporter 2 Inhibitor
7%
Hypertension
7%
Diuretics
7%
Frailty
7%
Electronic Health Record
6%
Blood Pressure
6%
Glucagon-Like Peptide-1 Agonist
6%
Exercise
6%
Secondary Prevention
6%
Drug Therapy
5%
Adipose Tissue
5%
Clinical Trial
5%
Troponin I
5%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
55%
Non Insulin Dependent Diabetes Mellitus
25%
Biological Marker
12%
Heart Failure with Preserved Ejection Fraction
8%
Liraglutide
8%
Cardiovascular Disease
7%
Randomized Clinical Trial
7%
Troponin I
7%
Hypertension
7%
Frailty
7%
Cardiovascular Risk
6%
Coronary Artery Atherosclerosis
5%
Chronic Kidney Failure
5%
Troponin T
5%
Natriuretic Factor
5%
All Cause Mortality
5%
Obesity
5%
Prevalence
5%
Keyphrases
Diabetes
20%
Type 2 Diabetes Mellitus (T2DM)
15%
Heart Failure
14%
Atherosclerotic Cardiovascular Disease (ASCVD)
13%
Pre-diabetes (pre-DM)
9%
Coronary Artery Calcium
8%
Type 2 Diabetic Patients
8%
United States
7%
Secondary Prevention
7%
Obesity
7%
Heart Failure Risk
6%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
5%